Related Experiment Videos
Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their
M Filippi1, M Rovaris, R Capra
1Neuroimaging Research Unit, Department of Neuroscience, Scientific Institute Ospedale San Raffaele, University of Milan, Milan, Italy.
Objective:
The ability of recombinant human interferon beta-1a (rh-IFN beta-1a) to suppress multiple sclerosis activity, evaluated from MRI, was assessed across a range of lesions enhancing at different gadolinium-DTPA (Gd) doses and with different sizes.
Methods:
Every 4 weeks, standard dose (Sd; 0.1 mmol/kg Gd) and triple dose (Td; 0.3 mmol/kgGd) MRI were obtained from 18 patients with relapsing-remitting multiple sclerosis for 3 months before and 4 months after starting treatment with 44 microgram rh-IFN beta-1a subcutaneously, once a week.
Results:
The total numbers of enhancing lesions were 145 and 126 on Sd scans and 278 and 192 on the Td scans obtained before and after treatment. The introduction of treatment decreased, on average, the rate of appearance of new enhancing lesions seen on Sd and Td scans by 37% (p<0.001). Treatment effects on new enhancing lesions seen on Td scans was, on average, 28% higher than on those seen on Sd scans. The distribution of lesion sizes on Td scans changed significantly during the treatment period (p=0.05), due to a marked decrease in the number of small lesions.
Conclusions:
The effect of 44 microgram rh-IFN beta-1a in reducing multiple sclerosis disease activity, as monitored by Gd enhanced MRI, is not homogeneous, but graduated according to the pathological characteristics and size of the lesions.
Insights
Recombinant human interferon beta-1a (rh-IFN beta-1a) effectively reduced multiple sclerosis (MS) lesion activity detected by MRI. The treatment
Area of Science:
- Neuroimmunology
- Radiology
- Pharmacology
Background:
- Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
- Recombinant human interferon beta-1a (rh-IFN beta-1a) is a therapeutic agent used in MS treatment.
- Magnetic Resonance Imaging (MRI) with gadolinium-DTPA (Gd) contrast is crucial for monitoring MS lesion activity.
Purpose of the Study:
- To evaluate the efficacy of rh-IFN beta-1a in suppressing MS activity.
- To assess treatment effects on enhancing lesions of varying sizes and at different Gd contrast doses.
- To understand the relationship between lesion characteristics and treatment response.
Main Methods:
- 18 relapsing-remitting MS patients received 44 microgram subcutaneous rh-IFN beta-1a weekly.
- Serial MRI scans with standard dose (Sd; 0.1 mmol/kg Gd) and triple dose (Td; 0.3 mmol/kg Gd) contrast were performed before and after treatment.
- The rate of new enhancing lesions and lesion size distribution were analyzed.
Main Results:
- rh-IFN beta-1a significantly reduced the appearance of new enhancing lesions by 37% (p<0.001) on both Sd and Td MRI.
- The treatment effect was more pronounced on Td scans (28% higher) compared to Sd scans.
- A significant decrease in the number of small enhancing lesions was observed on Td scans during treatment (p=0.05).
Conclusions:
- The efficacy of rh-IFN beta-1a in reducing MS activity, as assessed by Gd-enhanced MRI, is not uniform.
- Treatment effects are graduated, varying with the pathological characteristics and size of the enhancing lesions.
- MRI monitoring reveals a differential impact of rh-IFN beta-1a on lesions of different sizes.